Researchers have discovered a three-drug combination that enhances the generation of CAR-T cells, a type of cancer immunotherapy, and could improve CAR-T cell production for clinical treatments. The study emphasizes the importance of T-memory stem cells (TSCM) linked to stronger and more lasting cancer responses. The findings demonstrate the advantages of pharmacological approaches over genetic approaches to enrich TSCM-like cells as most gene-targeted therapies have not proven to be very effective in this arena.